Safety and efficacy of liposomal doxorubicin in a patient treated for metastatic breast cancer
Journal Title: OncoReview - Year 2015, Vol 5, Issue 4
Abstract
Breast cancer is the most common malignancy among women in Poland and all over the world. Despite the development of modern therapies, cytostatics still play one of the main roles in treatment of this disease. Classic anthracyclines, besides unquestionable efficacy in this disease, have a disadvantageous toxicity profile. Therefore, until now, there has been a limitation in using these drugs in patients with cardiological conditions and in patients who had previously taken anthracyclines. That was the cause for the development of a less toxic form of drug, which is liposomal doxorubicin – being as effective as classic anthracycline it has reduced cardiotoxicity. This article presents the case of a patient with metastatic breast cancer, in whom, after treatment with classic doxorubicin, liposomal form was administered which caused regression of liver metastases. Moreover, during treatment with liposomal doxorubicin, there has been no evidence of heart impairment.
Authors and Affiliations
Justyna Borucka
Keywords
Related Articles
- EP ID EP78726
- DOI 10.5604/20828691.1189724
- Views 214
- Downloads 0
Side effects control in the chemotherapy with everolimus: single-center experience
BACKGROUND: Renal cell carcinoma (RCC, renal cell carcinoma) accounts for 80–85% of neoplasms arising from the kidney. Everolimus, one of the selective mTOR kinase inhibitors, was recently approved for the treatment of p...
“Life-saving” inappropriate implantable cardioverter-defibrillator shocks in a cancer patient
Impaired left ventricular ejection fraction (LV EF) in patients with cancer can disqualify them from targeted antineoplastic treatment. We present the case of 63-year-old male with gastric cancer treated palliatively, wi...
Limfohistiocytoza hemofagocytowa (HLH) indukowana przez chłoniaka – opis przypadku
Limfohistiocytoza hemofagocytowa (HLH) to rzadki (zwłaszcza u dorosłych) zespół objawów, w którym hiperzapalenie powoduje gorączkę, hepatosplenomegalię, pancytopenię i bez leczenia prowadzi do zgonu. Wśród wyników badań...
Aktywność fizyczna a nowotwory
Dane epidemiologiczne wskazują, że aktywność fizyczna zmniejsza ryzyko wystąpienia raka piersi i raka jelita grubego. Najprawdopodobniej przyczynia się również do obniżenia ryzyka zachorowania na raka prostaty, trzonu ma...
Role of molecular examinations in qualification to first line treatment with erlotinib in NSCLC patients based on EURTAC study results
Between 2010–2011 the first EGFR thyrosine kinase inhibitor (EGFR TKI) – gefitinib, was registered in many countries in I line of treatment in patients with advanced and locally advanced non-small cell lung cancer (NSCLC...